Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]
Discontinued
Reference number: GID-TA10585
The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of nivolumab in combination with ipilimumab for untreated metastatic non-small-cell lung cancer ID1675.
We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal. However, the company that markets nivolumab and ipilimumab has advised NICE that they are no longer pursuing a licence in the UK for these products for this indication. In light of this information NICE will not be progressing with the scoping and appraisal exercise and consequently the scope consultation will be closed early.
If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on 44 (0)161 413 4070 or via email on emily.richards@nice.org.uk